KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.40
+1.00 (0.40%)
AAPL  275.64
+6.21 (2.30%)
AMD  238.49
-5.49 (-2.25%)
BAC  53.66
+0.24 (0.46%)
GOOG  292.13
+1.54 (0.53%)
META  627.83
-3.93 (-0.62%)
MSFT  509.23
+3.23 (0.64%)
NVDA  193.31
-5.74 (-2.88%)
ORCL  235.79
-5.04 (-2.09%)
TSLA  439.02
-6.21 (-1.39%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.